Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | F2R | P25116 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399169 | 1.00 | L3MBTL1 (0.61) | L3MBTL1MAPTF2RPOLBNPC1 | |
| SCHEMBL1399055 | 0.99 | L3MBTL1 (0.60) | L3MBTL1MAPTF2RPOLBNPC1 | |
| SCHEMBL1399085 | 0.99 | L3MBTL1 (0.60) | L3MBTL1MAPTF2RPOLBNPC1 | |
| SCHEMBL1399057 | 0.99 | L3MBTL1 (0.60) | L3MBTL1MAPTF2RPOLBNPC1 | |
| SCHEMBL1399084 | 0.99 | L3MBTL1 (0.60) | L3MBTL1MAPTF2RPOLBNPC1 | |
| SCHEMBL1399117 | 0.86 | C3AR1 (0.49) | L3MBTL1MAPTPOLBHRH3KCNH2 | |
| SCHEMBL1399116 | 0.86 | C3AR1 (0.49) | L3MBTL1MAPTPOLBHRH3KCNH2 | |
| SCHEMBL1399104 | 0.85 | C3AR1 (0.51) | L3MBTL1MAPTPOLBHRH3KCNH2 | |
| SCHEMBL1399106 | 0.85 | C3AR1 (0.51) | L3MBTL1MAPTPOLBHRH3KCNH2 | |
| SCHEMBL1399127 | 0.84 | ALDH1A1 (0.61) | L3MBTL1MAPTPOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022064-B2 | Phenylpentadienoyl derivatives and their use as PAR 1 antagonists | PIERRE FABRE MEDICAMENT (FR) | 2011-09-20 | — | — | US | claimed |
| EP-2046748-B1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PF MEDICAMENT (FR) | 2011-03-02 | — | — | EP | claimed |
| US-20100003260-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-07 | — | — | US | claimed |
| US-8022064-B2 | Phenylpentadienoyl derivatives and their use as PAR 1 antagonists | PIERRE FABRE MEDICAMENT (FR) | 2011-09-20 | — | — | US | disclosed |
| EP-2046748-B1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PF MEDICAMENT (FR) | 2011-03-02 | — | — | EP | disclosed |
| US-20100003260-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003260-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | F2R, F2RL1, FPR1 | L3MBTL1 2246/4885MAPT 3903/4885F2R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.